Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model

CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce preliminary results from its preclinical study of MB-204 in the Shank3Δex13-16 mouse model, a model associated with Phelan-McDermid syndrome. The study was conducted in collaboration with Dr. Julie Le Merrer and Dr. Jérôme Becker at the iBraiN Institute in Tours, France, and evaluated MB-204 at oral doses of 1 mg/kg and 2.5 mg/kg compared with Istradefylline at 1 mg/kg, the highest dose tested that did not affect locomotion.   Animals were studied for one to three hours post dosing. Istradefylline is a clinically approved drug for the treatment of Parkinson’s Disease.